The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1093 Ozempic articles
Semaglutide prices in India have plummeted by up to 90% following the launch of over 15 generic versions just days after patent expiry. Major players like Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco are offering affordable options for type 2 diabetes and obesity management. This shift promises greater access to this vital GLP-1 agonist therapy.
Recent trials show about 10% of people using Wegovy and Ozempic experience minimal weight loss, classified as 'non-responders.' Despite average reductions of 15-20%, stories like Samantha Jess's highlight real challenges. Discover why GLP-1 drugs don't work for everyone and how to optimize results.
New research paints a stark picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. Published in BMJ Medicine, the study tracked over 333,000 adults and warns of 'metabolic whiplash.' Patients face weight regain, inflammation resurgence, and lasting scars from interruptions.
Trials show one in ten people on Wegovy and Ozempic lose less than 5% of their body weight, challenging the drugs' reputation as a universal solution. Patient experiences like Samantha Jess's highlight non-responder realities, while experts explain genetic and metabolic factors. Discover why GLP-1 agonists work for some but not others.
With Novo Nordisk's semaglutide patent expiring, Indian drugmakers like Sun Pharma and Dr Reddy's are rushing generics while partnering with food giants for muscle-preserving nutrition. This GLP-1 boom addresses 25-40% lean muscle loss in weight reduction. Learn how companies like Mankind and Amul are reshaping obesity care.
GLP-1 drugs like Ozempic and Wegovy deliver impressive weight loss, but regain is common after stopping. A new Phase 2 trial of oral ARD-201 aims to change that by regulating appetite via bitter taste receptors. Led by obesity expert Lawrence Cheskin at George Mason University, this study targets post-treatment weight maintenance.
Semaglutide's patent expiry in India has flooded the market with affordable generics, dropping prices from over ₹10,000 to as low as ₹1,300 per month. While this opens access for millions with Type 2 diabetes and obesity, experts warn of safety risks from misuse without proper guidance. Discover the implications for patients and the growing market.
New research paints a grim picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. A Washington University study of over 333,000 patients highlights the 'metabolic whiplash' of discontinuation. Understand the findings and why adherence matters.
GLP-1 medications like Ozempic are reshaping America's waistlines—and its freight lanes. With 12% of U.S. adults adopting these appetite-suppressing drugs, food demand is down 3%, slashing millions of truckloads from snacks, beverages, and more. This public health trend is quietly disrupting the trucking industry.
